This is a challenging time to be running a drug maker.
To be sure, there is plenty of positive news. Congress heeded the call to pass legislation for speeding drug approvals. The Trump administration installed a Food and Drug Administration commissioner who is sympathetic to industry. More innovative medicines are finding their way to patients. And despite criticism over pricing, Congress has not taken any steps that might displease drug makers.